Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing

Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing

Submitted by admin on January 28, 2025 - 10:41am
Source: 
Fierce Biotech
News Tags: 
Maze Therapeutics
IPOs
kidney disease
clinical trials
Headline: 
Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing
snippet: 

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial.

Do Not Allow Advertisers to Use My Personal information